Spring 2011

Ultrasonic assisted layer-by-layer assembly for stable nanocolloids of Curcumin and Paclitaxel

Zhiguo Zheng

Follow this and additional works at: https://digitalcommons.latech.edu/dissertations

Part of the Biomedical Engineering and Bioengineering Commons, and the Other Pharmacy and Pharmaceutical Sciences Commons
ULTRASONIC ASSISTED LAYER-BY-LAYER ASSEMBLY
FOR STABLE NANOCOLLOIDS OF
CURCUMIN AND PACLITAXEL

by

Zhiguo Zheng, M S

A Dissertation Presented in Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy

COLLEGE OF ENGINEERING AND SCIENCE
LOUISIANA TECH UNIVERSITY

May 2011
We hereby recommend that the dissertation prepared under our supervision
by
Zhiguo Zheng

entitled
"ULTRASONIC ASSISTED LAYER-BY-LAYER ASSEMBLY
FOR STABLE NANOCOLLOIDS OF CURCUMIN AND PACLITAXEL"

be accepted in partial fulfillment of the requirements for the Degree of
Doctor of Philosophy in Biomedical Engineering

Supervisor of Dissertation Research

Head of Department

Department

Advisory Committee

Approved

Approved

Director of Graduate Studies

Dean of the Graduate School

Dean of the College

GS Form 13a
(6/07)
ABSTRACT

Researchers have been trying to fight cancer with synthesis of new bioactive compounds but many of these novel drugs have low solubility in water and it is difficult to deliver them into a patient’s body. One way of solving this particular problem is to use nanoscale drug delivery systems. In this dissertation, we describe using an ultrasonic assisted layer-by-layer encapsulation process to prepare anti-cancer drugs with 50–200 nm particle size with designed coating to achieve sustained release and target delivery.

Two methods for systematic manufacture of low solubility anti-cancer drug nanoparticles were proposed: 1) Top-down approach to breakdown larger drug crystals into nano-size particles; 2) Bottom-up approach to fabricate nano-size drug crystals from a drug solution.
APPROVAL FOR SCHOLARLY DISSEMINATION

The author grants to the Prescott Memorial Library of Louisiana Tech University the right to reproduce, by appropriate methods, upon request, any or all portions of this Dissertation. It is understood that "proper request" consists of the agreement, on the part of the requesting party, that said reproduction is for his personal use and that subsequent reproduction will not occur without written approval of the author of this Dissertation. Further, any portions of the Dissertation used in books, papers, and other works must be appropriately referenced to this Dissertation.

Finally, the author of this Dissertation reserves the right to publish freely, in the literature, at any time, any or all portions of this Dissertation.

Author [Signature]

Date 5/12/2011

GS Form 14 (5/03)
# TABLE OF CONTENTS

**ABSTRACT** iii

**LIST OF FIGURES** viii

**LIST OF TABLES** xi

**ACKNOWLEDGMENTS** xii

**ABBREVIATIONS** vi

**CHAPTER 1 INTRODUCTION** 1

1 1 Motivation 1

1 2 Outlines 2

1 2 1 Objectives of the study 2

1 2 2 Outline of the dissertation 2

**CHAPTER 2 NANOSCALE DRUG DELIVERY SYSTEM** 3

2 1 Nanoscale Drug Delivery System 3

2 2 Current Nanoscale Drug Delivery System 6

2 2 1 Drug conjugate 6

2 2 2 Dendrimer 8

2 2 3 Micelles 8

2 2 4 Microemulsion 9

2 2 5 Vesicles 10

2 2 6 Core-shell nanoparticles 11

2 2 7 Nanotubes 12
2.3 Layer-by-layer Coated Nanoparticles for Drug Delivery

2.3.1 Outline of LbL assembly

2.3.2 Recent progress of LbL microshells in drug delivery functions

CHAPTER 3 INSTRUMENTATION AND MATERIALS

3.1 Ultrasonicator

3.2 Zeta Potential Analyzer

3.3 Dynamic Light Scattering

3.4 X-Ray Diffractometer

3.5 SEM

3.6 Ultra Violet Spectrophotometer

CHAPTER 4 DRUG NANOPARTICULATION VIA TOP-DOWN APPROACH

4.1 Methodology

4.2 Curcumin Nanoformulation

4.2.1 Preparation of curcumin nanoparticles

4.3 Nanoformulation of Paclitaxel

CHAPTER 5 DRUG NANOPARTICULATION VIA BOTTOM-UP APPROACH

5.1 Methodology

5.2 Curcumin Nanoformulation

5.2.1 Nanocurcumin preparation

5.3 Paclitaxel Nanoformulation

5.3.1 Preparation of nanopaclitaxel

CHAPTER 6 PROCESS OPTIMIZATION

6.1 Ultrasonication Time

6.2 Water Add-in Speed and Drug Concentration
LIST OF FIGURES

Figure 2-1 Classification of nanoscale drug delivery System a) drug conjugate, b) dendrimer, c) micelle, d) microemulsion, e) vesicle, f) core-shell nanoparticle, g) nanotube 6

Figure 2-2 LbL assembly process outline 15

Figure 2-3 Preparation of functional hollow shells 17

Figure 2-4 Organometallic polyelectrolyte multilayer microshells, composed of polyamons and polycations of poly(ferrocenylsilane) 20

Figure 2-5 Degradable polymer microshells as carriers for the delivery of oligopeptide antigens 21

Figure 2-6 Self-explooding polyelectrolyte coated gel beads releasing micrometer-sized shells at the time of explosion 24

Figure 3-1 Hielscher UIP1000hd ultrasonic processor 30

Figure 3-2 Zeta potential analyzer by Brookhaven Instruments, Co 32

Figure 3-3 Precision detectors PDExpert light acattering workstation 34

Figure 3-4 Bruker D8 Discover X-ray diffractometer 35

Figure 3-5 Hitachi S-4800 scanning electro microscope 36

Figure 3-6 Agilent 8453 UV-Vis spectrophotometer 37

Figure 4-1 Scheme for top-down approach 40

Figure 4-2 Structural formula for curcumin 40

Figure 4-3 $\xi$-potential alternation during LbL-shell formation of cationic PAH and anionic PSS on curcumin nanoparticles Standard deviation shows the same sample run 10 times on zeta potential analyzer 42

Figure 4-4 SEM image of the formed curcumin nanoparticles (left) diluted sample, and (right) concentrated sample 43

Figure 4-5 Structural formula for pachtaxel 44
Figure 4-6 ξ-potential of paclitaxel coated with two different bilayers of PAH-PSS-PAH-BSA and PAH-PSS-chitosan-alginic acid (using top-down approach) Standard deviation shows the same sample run 10 times on zeta potential analyzer

Figure 4-7 SEM image of orginal paclitaxel (left) and after ultrasound assisted LbL encapsulation with PAH/PSS/chitosan/alginic acid (right)

Figure 5-1 Scheme of the bottom-up curcumin LbL nanoformulation

Figure 5-2 Particle ξ-potential alternation during LbL coating of curcumin (pH 6 5) Standard deviation shows the same sample run 10 times on zeta potential analyzer

Figure 5-3 SEM images of initial curcumin powder (left) and resulting curcumin nanocolloid (right)

Figure 5-4 X-ray diffraction spectra for micronized curcumin powder (upper spectrum) and for nanoformulated curcumin (lower spectrum)

Figure 5-5 ξ-potential change during the LbL encapsulation of paclitaxel Standard deviation shows the same sample run 10 times on zeta potential analyzer

Figure 5-6 SEM image of paclitaxel nanoparticles with shells of (PS/PSA)₂ (left), same sample showing aggregation of particles at another site (right)

Figure 5-7 SEM image of paclitaxel in 60 % ethanol sonicate for 45 min before (left) and after (right) centrifuge

Figure 6-1 Decrease of curcumin nanoparticles size as a function of sonication time in the presence of polycation Standard deviation shows the same sample run seven times on 90Plus particle sizer

Figure 6-2 Dependence of curcumin particle size on water addition rate Standard deviation shows the same sample run seven times on 90Plus particle sizer

Figure 6-3 Dependence of curcumin particle size on curcumin concentration Standard deviation shows the same sample run seven times on 90Plus particle sizer

Figure 7-1 Release test side-by-side diffusion cell set up (Scheme of side-by-side cells kindly provided by PermeGear, Inc)

Figure 7-2 Release profiles of curcumin in original micropowder form, after nanoparticulation and prepared with LbL nano-encapsulation (the shell composition (PS/BSA)₂)
Figure 7-3 Release curves for the original micronized powder of paclitaxel, uncoated paclitaxel nanoparticles (only one PAH layer adsorbed for colloidal stabilization) and nano-encapsulated paclitaxel with (PAH/BSA)₂ shell composition.

Figure B-1 Simulation for 200 nm sphere sharp paclitaxel concentration at 0.5 mg/mL (left) and 5 mg/mL (right).

Figure B-2 Simulation for 200 nm cube sharp paclitaxel concentration at 0.5 mg/mL (left) and 5 mg/mL (right).

Figure C-1 Fitting result for curcumin release.

Figure C-2 Fitting result for paclitaxel release.
# LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table A-1</td>
<td>Minimum amount of polyelectrolyte needed for coating</td>
<td>73</td>
</tr>
<tr>
<td>Table B-1</td>
<td>Average distance between sphere particles</td>
<td>75</td>
</tr>
<tr>
<td>Table B-2</td>
<td>Average distance between cube particles</td>
<td>75</td>
</tr>
<tr>
<td>Table C-1</td>
<td>Fitting results for the curcumin release profile</td>
<td>80</td>
</tr>
<tr>
<td>Table C-2</td>
<td>Fitting results for the paclitaxel release profile</td>
<td>81</td>
</tr>
</tbody>
</table>
ACKNOWLEDGMENTS

I would like to express my gratitude and appreciation to my advisor, Dr. Yuri Lvov, for his guidance and suggestions all through this dissertation project. I would also like to thank other members of my Advisory Committee and Dr. Tanya Shutova for her friendly guidance.
ABBREVIATIONS

BBB  Blood-Brain Barrier
BSA  Bovine Serum Albumin
DDS  Drug Delivery System
DLS  Dynamic Light Scattering
EDX  Energy Dispersive X-ray spectrometry
EPR  Enhanced Permeation and Retention
HPMA Hydrolyzed PolyMaleic Anhydride
LbL  Layer-by-layer
PAH  Poly(allylamine hydrochloride)
PEG  Poly(ethylene glycol)
PEI  Poly(ethylenimine)
PS  Protamine Sulfate
PSS  Poly(styrenesulfonate sodium)
PDDA Poly(dimethyldiallyl ammonium chloride)
QCM  Quartz Crystal Microbalance
QELS  Quasi-Elastic Light scattering
SEM  Scanning Electron Microscope
XRD  X-Ray Diffraction
CHAPTER 1

INTRODUCTION

1.1 Motivation

Cancer is the second leading cause of death in the United States. The National Cancer Institute estimated that 1,529,560 men and women (789,620 men and 739,940 women) will be diagnosed with, and 569,490 men and women will die from various of cancer in 2010 [1].

Researchers had been trying to fight cancer with new natural or synthetic bioactive compounds. Although these novel compounds showed promising results in screening process, many of them exhibit low solubility in water because of the hydrophobic and/or polycyclic nature. Low solubility often brings challenges to drug administration, because the traditional formulation usually cannot provide enough of the bioavailability required for treatment. Also, many of these compounds are highly toxic to normal cells so targeted delivery of the drug to the tumor tissues is required. One way of solving the problem is to establish a drug delivery system that uses nano size drug particles with appropriate coating. Our project will use an ultrasonic assisted layer-by-layer encapsulation process to prepare anti-cancer drug with 50–200 nm size with a designed coating to achieve sustained release and targeted delivery.
1.2 Outlines

1.2.1 Objectives of the study

We developed the following directions in our work

1. We will systematically establish a process to fabricate nano size, low solubility drug particles (paclitaxel and curcumin)

2. We will optimize the process established in 1 to reduce the drug particle size

3. We will compare different layer-by-layer coatings for sustained release

1.2.2 Outline of the dissertation

This dissertation is arranged into eight chapters. Chapter 1 provides an introduction to the dissertation by describing the motivation and purpose of the study as well as the outline of the dissertation. Chapter 2 is the literature review, in which we will discuss nanoscale drug delivery systems in general and compare different types of existing nanoscale drug delivery systems. This is followed by a short introduction to the layer-by-layer self-assembly coating drug delivery system. In Chapter 3, we introduce the material, instruments, and general methods that were used in this research. Chapter 4 is focused on the top down approach which breaks down big drug particles into nano size particles. Chapter 5 will show a different bottom up approach which forms nano crystals from solution using ultrasound. Chapter 6 will optimize particle size by changing various parameters, like sonication time and concentration. Chapter 7 will study the release profile of different nano drug particles. The main accomplishments of the dissertation work are summarized in Chapter 8, with directions for further research.
CHAPTER 2

NANOSCALE DRUG DELIVERY SYSTEM

2.1 Nanoscale Drug Delivery System

With the application of nanotechnologies to medicine, a new branch of nanotechnology, called nanomedicine, has been rapidly developed [2] Nanoscale drug delivery systems use nanosize drug carriers to deliver drugs to the desired sites And often use active or passive targeting strategies to increase local concentration at the tumor tissue [3]

Goals of a nanoscale drug delivery system include

1 Improved solubility To increase the drug bioavailability
2 Targeting To increase the local concentration of the drug at desired sites
3 Adjustable rate of drug release To maintain a constant dose at the action site
4 Reduced drug clearances To increase the drug half-life
5 Enhanced stability To reduce drug degradation during storage
6 Drug delivery across biobarriers like the blood-brain barrier (BBB)

The goals of the drug delivery system were to deliver the conjugated or bound drug-carrier complex to the selected target and maximize act at desired cancer sites Controlled delivery of the drug molecules using carrier materials are based on two types of strategies active and passive targeting Although the former has very sophisticated strategies, its practical use still suffers from many technical difficulties The latter is
more practical, and there are already many formulations based on “enhanced permeability and retention effect” [4, 5], which has been the most representative passive-targeting strategy to bring drug molecules to tumors.

The active targeting strategy of the drug nanocarrier was to use a ligand, attached on the nanocarrier, specific for the receptor of the target tissue. Passive targeting strategy of the drug nanocarrier was to use the enhanced permeation and retention (EPR) effect of the cancer tissue. Tumor and inflamed tissue tend to have excessively leaky microvasculature, compared to normal endothelium, which allows the drug nanocarrier to diffuse through and accumulate at site. Especially for cancer tissue, overexpression of vascular endothelial growth factor will increase vascular permeability and let to complicated tumor-vessel architecture. Transvasation of drug carrier takes place either via transcytosis, where by macromolecules are internalized from the blood at points of invagination of the cell membrane, or paracellularly, via diffusion through the tight junctions of endothelial cells. In combination, these effects cause enhanced permeation and retention (EPR), resulting in high local drug concentrations.

For nanoscale drug delivery systems, biocompatibility and biodegradability have always been considered as one of the most important properties. The unloaded carrier should be able to biodegrade or metabolize into nontoxic components and cleared through the circulation system. Some studies suggested nanoparticles are cleared according to size. Small particles (<30 nm) are rapidly cleared by renal excretion. Nanocarriers >30 nm are cleared by the mononuclear phagocytic system, consisting of macrophages located in the liver (Kupffer cells) and the spleen [6], which act as phagocytotic scavengers. Clearance is also dependent on the endothelial fenestral pore.
size [6] Fenestral pore size values are highly variable for different patients. Clearance rate of patient could be affected by sex, age and genetics factors. It is difficult to determine the efficiency and toxicity of nanomedicines in different individuals. Whether nanocarriers are taken up by macrophages depends on opsonization by the innate immune system [7]. Molecules that bind to foreign materials and enhance phagocytosis, include IgG and IgA antibodies, the complement cascade system and mannose-binding lectin [8]. Therefore, the surface properties of nanocarriers can significantly affect the rate of clearance by the MPS. A useful method for evading opsonization of large narrow carriers was developed at Rutgers University [9] in a process called PEGylation, a polymer, poly(ethylene glycol) (PEG, \([\text{CH}_2\text{CH}_2\text{O}]_n\)), is conjugated to the drug carrier preventing drug particles aggregation and precipitation.

Overall, the use of ligand binding nanodrugcarrier will improve the drug therapeutic index according to Equation (1)

\[
\text{Therapeutic index} = \frac{\text{Maximum non-toxic dose}}{\text{Minimum effective dose}}
\]  

(Eq 1)

The high specificity and selectivity of the ligand on nanodrugcarrier increases the amount of drug delivered to the cancer tissue and decreases the amount of drug at unwanted sites. Therefore, a less systemic drug dose needs to be administered to guarantee an effective concentration at the site of action, and the minimum efficacious dose is also lower. In addition, because less drug is present at unwanted sites, the maximum non-toxic dose is higher. The overall effect is a significant decrease in toxicity and adverse side effects.
2.2 Current Nanoscale Drug Delivery System

Nanoscale drug delivery systems can use different kind of nanoparticles as carriers. In this section we will review some of the most common category of nanoparticles can be used as drug delivery systems. Figure 2-1 shows the structure schematics of these nanoparticles.

![Diagram of Nanoparticles]

**Figure 2-1** Classification of nanoscale drug delivery System  
(a) drug conjugate, (b) dendrimer, (c) micelle, (d) microemulsion, (e) vesicle, (f) core-shell nanoparticle, (g) nanotube

### 2.2.1 Drug complex and conjugate

Drug complexes and conjugates do not have a defined structure like micelle or vesicle. Drug complexes depend on reversible interactions between carrier and drug.
Drug conjugates use covalent bonds to join carrier and drug together [10] Drug conjugates can be prepared using chemical reactions of functional groups between the drug and the carrier molecular. There are two major categories of drug complexes and conjugates: one is protein and peptide associated and the other is polymer associated. Proteins and peptides can be used to form nanostructures in various ways, including complexation. An example of protein associated drug complex nanoparticle for clinical use is Abraxane™. Abraxane™ is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. Paclitaxel exists in the albumin-bound particles in a non-crystalline form. Abraxane™ is formed by dissolving paclitaxel in water immiscible methylene chloride, and adding this to a solution of human serum albumin in water with low-speed homogenization. This process creates an emulsion with albumin located at the aqueous-solvent interface. Subsequent high-pressure homogenization reduces the particle size and breaks and reforms the disulfide bonds, essentially cross-linking the albumin coating and stabilizing the particle. An evaporation step volatilizes the methylene chloride, leaving an aqueous suspension of 140-160 nm nanoparticles, consisting of an amorphous paclitaxel core surrounded by a 25 nm coating of albumin with bound paclitaxel. Because of its size, this material can be sterile filtered [11, 12]. Abraxane™ does not contain the problematic solvent - Cremophor EL, which outperformed conventional paclitaxel at an equitoxic dose while decreasing toxicity, due to longer circulation time and lower off-target activity [13, 14]. Supramolecular complexes between host and guest molecules are also considered as useful for the drug administration. Cyclodextrins are natural products and can entrap entire or part of guest drugs in their inside cavity in a specific mode. Chemical modification of natural cyclodextrins molecular could improve their efficacy by altering
their solubility or capacity for the guest drugs. Cyclodextrins are regarded as useful additive in drug delivery systems [15, 16]

2.2.2 Dendrimer

Polymeric dendrimer is a kind of hyperbranched nanostructures. One of dendrimers’ advantages is that its size can be controlled by adjusting the number of polymerization generations. During the polymerization process, monomer molecules joined into a spherical nanostructure. Inside this dendrimer nanostructure are cavities which allowed therapeutic agents to be loaded with great loading efficiency [17].

The polymerization progresses of dendrimers can be precisely controlled to obtain the desired final product. The molecular weight, chemical composition, and nanostructure of the final product can be precisely designed [18]. With controlled polymer structure and narrow polydispersity, dendrimers may be ideal platforms for drug delivery system. An example of dendrimers for clinical usage is VivaGel™. It is currently on trial for safety and efficacy as a microbicidal.

2.2.3 Micelles

Micelles are one of the simplest molecular assemblies and can carry hydrophobic drugs in their central core or in their palisade layer [19]. Micelles nanoparticles are interesting structures for carriers of drugs because they can form relatively uniform size structures. Micelles can be formed using a variety of amphiphilic materials as outside coating and using hydrophobic drug as central core, and can incorporate multiple functionalities into a single structure. Unfortunately, surfactants used to form micelles often have toxic effects on human bodies. Only a few kinds of surfactant are approved by FDA for drug solubilization. Additional use of organic solvents may increase drug solubility but disturbs micelle formation in some cases [20,
Lacking an aqueous core, the drug must be bound to the polymer before micelles form. Drug needs to be conjugated to an anchor polymer molecule, or entrapped and bonded inside the hydrophobic core of the micelle [22] Micellar structures, including polymeric micelles, have been extensively studied as drug carriers [23] Polymeric micelles made of hydrophilic-hydrophobic block copolymers are used as drug carriers [34] which can be concentrated in the tumor tissue based on the EPR effect [25], and may be used for gene therapy as well [26] Because hydrophilic-hydrophobic block copolymers' critical micelle concentrations are much lower than those for low-molecular-weight surfactants, they have higher stability and lower toxicity The hydrophobic portion of the copolymer forms the micellar core The hydrophilic block of the copolymer forms the micellar corona This corona (commonly consisting of PEG, HPMA, or other hydrophilic polymers) confers these micelles with biocompatibility, stealth-like properties, and a platform for functionalization [27-29] Genexol-PM™ is a formulation of paclitaxel encapsulated in a polymeric micelle formed by the solid dispersion technique from the biodegradable block copolymer, monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) [30] Several clinical trials have already been carried out evaluating the safety and efficacy of Genexol-PM™ in metastatic breast cancer, solid tumors, and non-small-cell lung cancer [31-33]

2.2 4 Microemulsion

Entrapment of drugs within emulsions [34] results in various improvements in the performance of the drugs including suppression of side effects, prolonged drug retention in blood circulation, and enhanced drug efficacy at the target site based on the EPR effect Lipid emulsions have a long history in the pharmaceutical practice as nutrients, commercialized emulsion formulation was achieved relatively easily by
incorporating hydrophobic drugs, such as steroids, into the traditional emulsions. Microemulsion is an equilibrated solution, unlike emulsions, and it is utilized for oral formulations [35-37]. Formulations containing surfactants, drugs, and oils, which were designed to spontaneously form microemulsions upon contact with water in the stomach and small intestine, induce reproducible drug release. This formulation offers great contribution to organ transplantation [38], since it requires precise control of the immunosuppressant concentration in plasma. Microspheres composed of appropriate polymers, such as biodegradable polymers, enable prolonged drug-release after intravenous injection. Administration frequency has decreased from daily to monthly by using this carrier [39].

2.2.5 Vesicles

Vesicular structures have been extensively studied as drug delivery system. The two major categories of vesicles are liposomes and polymer vesicles. Vesicles have the capacity for encapsulation of hydrophobic or hydrophilic drugs. Vesicles can be designed to use covalent or non-covalent bonds to load drugs. Liposomes, (or lipid vesicles) [40] can be used to load hydrophilic drugs into an interior aqueous phase. Liposomes can also be used to load hydrophobic drug lipid phase in the shell. Liposomes are considered to be ideal drug carriers, because of their surface characteristics can be altered easily and their size is controllable. Use of liposomes as a clinical drug delivery system still need to face some technical difficulties like mass production, storage stabilities, and lack of efficacy after accumulating at the target site. Recently, liposomes have also been studied as non-virus vectors for gene therapy [41]. Liposome formulations for drug delivery have been in development for almost half a century, and have produced clinically successful applications [42]. Polymeric vesicle structures, or
polymersomes, have been described more recently, and have unique potential as drug carriers. An example of the clinical vesicle formulation is Doxil™, also known as liposomal Dox. Encapsulation of Doxorubicin in liposomes shielded by polyethylene glycol (PEG) prolongs systemic drug circulation, improves safety, and increases the therapeutic index relative to free Doxorubicin [44, 45].

### 2.2.6 Core-shell nanoparticles

Core-shell structured nanoparticles consist of an inner nanoparticle core and a hydrophilic shell. The inner nanoparticle core could be made with a wide variety of materials including Quantum-dots, metals, metal oxides, and polymers among other materials. The core is surrounded by a hydrophilic shell usually using covalent or ionic bonds or electrostatic force.

One category of core-shell nanoparticles has been developed during the chemical modification of gold and other materials nanoparticles to increase their physiological stability and control drug association and release [46]. These core-shell nanoparticles offer stability and modifiable surface properties, and can even produce contrast depending on their composition, size, and shape [47, 48]. These core-shell structured nanoparticles make for a very robust drug delivery vehicle due to the vast variety of elements that can be used as the core and shell components. Despite the advantages already mentioned, these core-shell nanoparticles suffer from some inherent shortcomings, such as biotoxicity, rapid clearance rate, and poor biodistribution and biodegradation. Various strategies are in development to circumvent these problems [49, 50].

Another category of core-shell nanoparticles uses porous materials as an inner core to carry drug. Porous materials with large surface area and pore volume are
regarded as good candidates for drug storage and delivery. As an example, mesoporous silica have been investigated as a drug carrier materials because of its mesochannels, which have defined diameters in the ranges of nanometers to tens of nanometers provide reliable nanospaces for drug accommodations [51, 52]. In addition, their huge pore volume per unit mass of materials enables us to entrap large amounts of drugs. In some pioneering approaches, the inlets of channels are modified to add gate functions, resulting in controlled release by external stimuli [51-53]. Not limited to mesoporous silica, mesoporous carbon and related materials [54, 55], biocompatible porous calcium phosphate [56], and metal-organic frameworks (MOF) [57] have also been paid attention as future strong candidates for drug delivery applications.

### 2.2.7 Nanotubes

Carbon nanotubes are used as drug carriers because of their nanocavities and high surface area [58, 59]. However, there is much concern regarding the long-term toxicity of the nanotubes in practical uses due to their geometrical similarity to asbestos [60]. Carbon nanohorns may be a better candidate for drug carrier [61] due to their lower aspect ratio, which is considered to play an important role in the toxicity. Carbon nanotubes (CNTs) are cylindrical tubes composed solely of carbon and can be formed either as single-walled or multi-walled, for more stability [62]. These CNTs are being investigated as therapeutic nanoparticles because of their tunable properties and ability to incorporate multiple functionalities. Amine-functionalized, single-walled CNTs were conjugated by amide-linking to a cisplatin-folic acid derivative as targeted delivery system, has showed better performance than a conventional cisplatin formulation [63].

Another study conducted by Rusling et al. used carboxylated single-walled CNTs conjugated with cisplatin and epidermal growth factor to target cancer cells.
which have overexpress of the epidermal growth factor receptor. The targeted CNT-cisplatin conjugate improved the selective killing of the targeted tumor cells [64] Many studies have reported CNTs to be effective carriers of therapeutics and imaging agents *in vitro*, however, *in vivo* studies have lead to concerns regarding the associated toxicities [65-67]

An interesting development was recently reported on drug delivery with halloysite clay nanotubes [68-71] These clay nanotubes have a larger diameter than carbon nanotubes (ca 50 nm external diameter, 15 nm lumen diameter and length of ca 800 nm), and they are biocompatible [72] Drugs may be loaded into these tubes within a minute at ca 10-20 wt % and then slowly released over 10-50 hours [69] It is not assumed that it would be possible to inject halloysite clay nanotubes into the bloodstream, due to their inorganic composition, but their applications for dermatological (including rectal), cosmetic and dental delivery were considered as well as incorporation into bone and tooth implants.

### 2.3 Layer-by-layer Coated Nanoparticles for Drug Delivery

#### 2.3.1 Outline of LbL assembly

Before we discuss the LbL capsules for drug delivery we will first briefly review the layer by layer self assembly technique in this section [73, 74] Self-assembly of the nanoparticles using electrostatic interactions through a layer-by-layer process, was first proposed by R K Iler [75] The idea was developed and first realized by Decher, Mohwald, Lvov, et al [76, 77] Because the self-assembling mechanism is so simple, the requirements for the apparatus necessary for the process are very low (requiring only beakers and tweezers) [78], and the procedures are easy to perform, this methodology was quickly adapted by many research groups with the utilization of layer by layer
assemblies of various materials including synthetic polymers [79-80], biomaterials [81-84], inorganic materials [85-87], and supra-molecular assemblies [88-90] Relatively high concentrations of the charged substances in the solution results in excess adsorption of the substances The surface charge was first neutralized and then resaturated lead to charge reversal (Figure 2-2) Reversing of the surface charge makes a continuous assembly between positively and negatively charged materials The driving forces for the LbL self-assemblies are not limited to electrostatic interactions Many kinds of interactions, such as metal coordination [91, 92], hydrogen bonding [93, 94], covalent bonding [95, 96], supramolecular inclusion [97], bio-specific recognition [98, 99], charge transfer complex formation [100], and stereo-complex formation [101, 102] were reported and could be used in the LbL process Many other deposition techniques including spin-coating [103, 104] and spraying [105], were used for the LbL assembly Also automatic machines were developed for the LbL assembly [106, 107] The materials used for LbL assembly also have been widely tested In the 90's, most researchers used synthetic polyelectrolytes, such as PAH, PEI, PDDA, PSS and PAA, but current research, especially related to biomaterials and pharmacology, uses natural biodegradable polyelectrolytes, including positively charged chitosan, dextran amine, gelatin A, protamine sulfate, and negatively charged chondroitin sulfate, dextran sulfate, hyaluronic acid, heparin, gelatin B and sodium alginate
The LbL assembly techniques are considered suitable for biomaterials, because the process is simple and is performed in mild environment. The LbL assembly is usually performed at room temperature in a pH neutral aqueous solution. Because the LbL technique does not require special conditions like high temperature or extreme pH, biomaterials can be assembled under favorable conditions. Another advantage of the LbL assemblies for biomaterials is the porous nature. Unlike Langmuir-Blodgett (LB) films, LbL films allow diffusion of materials. Activities of the enzyme glucose oxidase were reported to be blocked after covering with only a few layers of lipid LB films [108, 109]. The LbL films with a single component enzyme (glucose oxidase) or multiple enzymes (glucose oxidase and glucoamylase) do not have a serious decrease in enzyme activity after an increase in the numbers of layers [110, 111]. These facts show that LbL films allow the diffusion of materials. This ability is a crucial factor in drug delivery functions. Additionally, it was also reported that biomaterials embedded within the LbL films show better stabilities [112].
An important development in the LbL technique was applying LbL technique to assembly on colloidal particles [113]. This technique was first developed by G Sukhorukov, E Donath, F Caruso, and H Mohwald in the Max Planck Institute for Colloids and Interfaces [113-122], and then was quickly adapted by other groups.

Instead of using conventional flat surface supports, LbL films were assembled sequentially on a colloidal core. Subsequent destruction of the central colloid particle core could lead to hollow shells. A typical example of preparing functional hollow shells is shown in Figure 2-3 where DNA molecules, retaining the natural double-helix structure, were encapsulated inside a biocompatible polyelectrolyte microshell [123, 124]. In the first step, MnCO₃ particles were used as template, cores were suspended in a DNA solution, and the addition of spermidine solution into stirred MnCO₃/DNA solution caused precipitation of a water-insoluble DNA/spermidine complex onto the MnCO₃ particle. Then in the second step, LbL assemblies of biocompatible polyarginine and chondroitin sulfate on the complex core were conducted. In the third step, dissolution of the MnCO₃ template particles resulted in biocompatible shells containing a DNA/spermidine complex. In addition, further decomposition of the DNA/spermidine complex led to a selective release of low molecular weight spermidine to complete the DNA entrapment. In another example, De Smedt and coworkers reported a labeling system for LbL drug delivery using the barcode concept with encoded fluorescent polystyrene with captured antibodies [124].
2.3.2 Recent progress of LbL microshells in drug delivery functions

The LbL microshells could be used in many applications including in life science [125-127] The LbL microsells used as drug carriers have been attracting a lot of attention Most LbL shells used in these applications have diameter at micrometer range Raichur et al reported encapsulation and release profiles of rifampicin, an antituberculosis drug, using hydrogen-bond assembly LbL microshells of poly(vinyl pyrrolidone) and poly(methacrylic acid) [128] Release profiles showed a burst release Above pH 7, the maximum release rate was achieved because the microshells rapidly disintegrate The rifampicin released from the LbL microshells shows the same efficacy as the free drug This result indicates the drug properties have not changed because of possible disturbances during the encapsulation and release process Zhao, et al reported the loading of doxorubicin, an anti-tumor drug, into preformed LbL microshells The doxorubicin loaded LbL microsells’ effect in tumor treatment was assayed by in vitro
cell culture tests and *in vivo* animal experiments [129] The LbL microshells contain negatively charged carboxymethyl cellulose which entraps levels of the positively charged doxorubicin ten to a hundred times higher than the feeding concentration. The encapsulated doxorubicin can effectively trigger the apoptosis of HepG2 tumor cells on *in vitro* tests. The result shows that the LbL microshells have the ability for drug delivery and cancer treatment on an animal experimental level. Chen, et al. encapsulated another anti-cancer drug artemisinin in the crystal form with LbL microshell containing chitosan, gelatin, and alginate using LbL technique [130] The release rate of artemisinin could be adjusted by various parameters, such as polyelectrolyte types, number of polyelectrolyte layers, sodium chloride concentration, and ethanol concentration in the polyelectrolyte solution.

Many researchers also try to control of drug release using external stimulation. Zhang, Gu, et al. synthesized alginate-templated magnetically sensitive LbL microshells [131] When a high-frequency magnetic field was applied, doxorubicin's drug release rate from the microshells was significantly increased. The doxorubicin-loaded microshells showed much lower cytotoxicity at the high drug concentration in comparison with doxorubicin. Choi et al. prepared LbL microshells containing photoacid generators, which made them UV sensitive [132] UV light will induce activation of photoacid generators and lead to the release of protons. The decrease in the pH of the solution triggered the swelling of the LbL microshells. Thus, opening and closure of the LbL microshell was achieved by exposure to UV light and washing with pH neutral water. In addition, prolonged UV light exposure led to the breakage of the LbL microshells, which results in rapid release of the entrapped drugs.
Protein delivery using LbL shells is also an active area in current research. Zhang, L1, et al reported encapsulation and controlled release of protein using biodegradable LbL microshells. The microshells consisted of dextran sulfate and chitosan. Bovine serum albumin (BSA) was used as the model protein. BSA was encapsulated in the LbL shells [133]. The cell viability test indicated that the LbL microshells had good biocompatibility. De Geest, Parak, et al encapsulated with a model of a nonactive prodrug, a self-quenched fluorescence-labeled protein in biodegradable LbL microshells [134]. After the microshells uptake by living cells, the walls of the microshells were degraded and digested by intracellular proteases. Wall degradation allowed intracellular proteases to reach the protein loaded inside of the microshells. Enzymatic fragmentation of the fluorescence-labeled protein leads to individual fluorescence-labeled peptides. So, only prodrugs inside the microshells that reach into the cells are the only ones activated, and those in shells in the extracellular environment cannot be activated. Akashi et al reported entrapped proteins inside biodegradable microshells via LbL assembly. Chitosan and dextran sulfate were assembled onto a protein-entrapping mesoporous silica particles, and then the silica was subsequent dissolved [135]. Sustained release of the encapsulated proteins was achieved by using the enzyme to degrade the hollow shells.

Variously specifically designed polymers have been used to compose the LbL microshells. For example, Vancso et al developed organometallic polyelectrolyte multilayer microshells, which are composed of polyanions and polycations of poly(ferrocenylsilane) (Figure 2-4) [136]. Poly(ferrocenylsilane) have redox-active ferrocene units in the main chain, which makes the shell wall permeability sensitive to the redox state. In fact, the permeability of these microshells can be tuned using...
chemical oxidation, resulting in a fast shell expansion accompanied by a significant permeability increase in response to a very small trigger.

Caruso et al. developed a new type of polymer hydrogel LbL microshells based on disulfide cross-linked poly(methacrylic acid) and poly(vinylpyrrolidone). The disulfide cross-linking is sensitive to redox state. It can act as redox-active trigger for shell degradation [137]. They also developed degradable LbL microshells as drug carriers for the delivery of oligopeptide antigens to antigen presenting cells (Figure 2-5) [138]. Oligopeptide sequences were first covalently linked to a negatively charged polymer via biodegradable linkages. Then this conjugate was adsorbed onto amine-
functionalized silica particles. The peptide-coated particle was coated with thiolated poly(methacrylic acid) (PMA$_{SH}$) and poly(vinylpyrrolidone) (PVPON). Dissolving of the silica core and disruption of the hydrogen bonding between polymers resulted in disulfide-stabilized microshells. Glutathione, a natural reducing agent, can be used to cut the disulfide bonds which causes release of the peptide from the microshells.

Figure 2-5 Degradable polymer microshells as carriers for the delivery of oligopeptide antigens.

Many researchers combine the LbL technique with other molecular assembly technique, such as liposomes or micelles, together to create various shell systems. Addison et al. developed LbL microshells constructed entirely from a cationic/ zwitterionic pair of pH-responsive block copolymer micelles [139]. Layers of anionic poly[2-(dimethylamino)ethyl methacrylate-block-poly(2-(diethylamino)ethyl methacrylate)] and cationic poly(2-(diethylamino)ethyl) methacrylate-block-poly(meth-
acrylic acid) copolymer micelles were alternately assembled onto CaCO₃ colloidal templates. Then add in dilute ethylenediaminetetraacetic acid solution to dissolve the CaCO₃ core and form hollow polymer microshells. This type of LbL microshells is composed entirely by pH sensitive block-copolymer has potential application for the encapsulation and triggered release of drugs. Li, Hu, et al. fabricated via a layer-by-layer technique, templated on CaCO₃ particles with built-in polymeric micelles based on polystyrene-b-poly(acrylic acid) [140]. This type of LbL microshell can selectively entrap positively charged substances such as rhodamine B and lysozyme. The positively charged substances can be entrapped in the shells where the concentration is much higher than that in the incubation solution. The encapsulated compounds shown sustain released to a certain degree, as suggested by in vitro release experiments. Caruso et al. reported using micelles for LbL assembly. They synthesis DNA-grafted poly(N-isopropylacrylamide) (PNIPAM) micelles, then assembly PNIPAM micelles into LbL films, and then use poly(ethylene glycol) (PEG) to functionalize the DNA–PNIPAM microcapsules [141]. The combination of hydrophobic core and alkyne “click” groups, along with the biodegradability of DNA, offers a multifunctional and versatile DNA–polymer capsule system that can be used for the controlled delivery of therapeutics.

Fukui and Fujimoto combined the liposome preparation and the LbL deposition together to prepare hollow shell structures [142]. Chitosan was deposited onto a negatively charged liposome surface and form a cationic polymeric layer. Then dextran sulfate or deoxyribonucleic acid was used to form an anionic polymers layer. They reported that chemical substances with different charges, alendronate, pyranine, and glucose, were encapsulated into microshells where the release rate was suppressed by
the polymer shell wall irrespective of charges [142]. Also they use DNA denaturation as a temperature dependent switch to achieve the temperature-dependent release. Tabrizian et al. developed a delivery system for bone growth factors consisting of a liposome core incorporated into a shell of LbL-assembled natural polyelectrolytes [143]. The prepared hydrophilic, monodisperse, spherical and stable cationic nanoparticles (< or =350 nm), as a delivery system, localized the effect of the released bone growth factors within the site of injection in muscle. Ramaye et al. developed a combination of magnetic liposomes and LbL assembling techniques [144]. Superparamagnetic nanoparticles were encapsulated in liposomes prior to the stepwise adsorption of LbL assembly. Magnetic field also allows a fast separation of coated liposomes from unbound polyelectrolytes.

The presence of magnetic nanoparticles and the polyelectrolyte shell opens allows to use external magnetic field to manipulate and target drug carriers.

Integrated shell structures have also been proposed. De Smedt et al. designed self-explooding gel beads that can release micrometer-sized shells at the time of explosion (Figure 2–6) [145]. The larger gel beads were loaded with small LbL microshells. When the polyelectrolyte coated gel beads explode under alkaline conditions, through rapid hydrolysis of the carbonate esters connecting the polymerized methacrylate groups with the dextran backbone, the smaller LbL microshells become suddenly released. Self-explooding gel beads releasing antigen containing LbL microshells at different times after injection could become promising materials for vaccination purposes. The reverse-phase was used to coat polymer layers onto agarose microbeads containing tris-buffer for the formation of LbL shell-walls onto the microbeads. The polymer-coated agarose microbeads were transferred from an organic to an aqueous solvent where the tris-molecules induced an osmotic pressure in the
The inflation of the LbL microshells caused the expansion of the LbL shell-walls. The inflated microshells can control localized chemical or enzymatic reactions that are useful in biomedical applications. Ke, et al. developed a bi-mode ultrasound/fluorescent imaging agent through LbL assembly of poly(allylamine hydrochloride) (PAH) and CdTe quantum dots onto microbubbles produced by sonication of a mixture of Span 60 and Tween 80 [147]. The Quantum-dot-modified microbubbles not only maintained the ability of ultrasound imaging, but also could be used as a targeted-drug controlled-release system to deliver the quantum dots by ultrasound targeted microbubble destruction.

Figure 2-6 Self-exploding polyelectrolyte coated gel beads releasing micrometer-sized shells at the time of explosion.
In conclusion for Chapter 2, layer-by-layer (LbL) nanoassembly is a simple method allowing the design of multilayer architectures with nanometer precisions. It is based on the alternate re-saturated adsorption of oppositely charged components, such as synthetic and natural polyelectrolytes, proteins and nanoparticles. The only rule of thumb is sequential adsorption of positively and negatively charged components resulting in any pre-determined composition multilayer film. One forms films consisting of bilayers of electrostatically bound cationic and anionic macromolecules, and the typical bilayer thickness is one to a few nanometers. Following the first LbL papers published in the beginning of the nineties by G. Decher, H. Mohwald, Y. Lvov, M. Rubner and others, one can find around 8,000 publications dealing with the LbL technique. It is interesting that until the last few years, the majority of these works were devoted to LbL assembly predominantly using sodium poly(styrene sulfonate) - PSS, poly(allylamine) hydrochloride-PAH and poly(ethylenimine)-PEI. These PSS, PAH, and PEI multilayers are the most studied, but, in recent years, researchers began using natural polyelectrolytes and proteins. Now, one can conclude that the LbL method works perfectly for the assembly of anionic compounds, such as alginic acid, hyaluronic acid, chondroitin sulfate, heparin, dextran sulfate, carboxymethyl cellulose, polyaminoacids, DNA, and cationic ones chitosan, dextran amine, polylysine, collagens, protamine sulfate, gelatin A, and others. Therefore, we have a group of biocompatible and biodegradable materials (in many cases FDA approved) and the LbL-technique to assemble them in a controllable manner in multilayers of 2-500 nm thickness.

How can these architectural multilayers be used for drug delivery? An answer is by formation of microcapsules loaded with drugs. Formation of LbL multilayers on tiny
templates and performing LbL encapsulation was first introduced in 1999 in Max Planck Institute, Germany by G Sukhorukov, E Donath, F Caruso, H Mohwald and Y Lvov. Generally, LbL encapsulation is the same method as described above for a planar substrate but applied to small 2-5 micrometer diameter drug particles or sacrificed polymeric, MgCO₃, CaCO₃ or silica cores. The possibility to design any thickness or composition of such LbL shells allowed control of drug diffusion from the capsules. For different drugs, the variation of the capsule wall thickness within 20-100 nm allowed release time from 10 min to 5 hours. This is the main idea for LbL encapsulation for controlled drug delivery.

Currently, one can indicate two methods in LbL encapsulation. 1) The more common approach for formation of LbL microcapsules on sacrificed cores, dissolution of such cores and loading empty LbL microshells with drugs or proteins through a pH dependable capsule wall pore opening. In this case, drug loading is 5-10%. The following drugs were analyzed for LbL encapsulation: ibuprofen, furosemide, nifedipine, naproxen, biotin, vitamin K3, insulin, dexamethasone, tamoxifen, paclitaxel. 2) The second direction is much less known (only four publications exist from LaTech’s group) using the LbL nanoencapsulation of low soluble drug nanoparticles (which allowed ca. 70-80% drug loading).

Therefore, in LbL capsules one can see two tendencies. Making microcapsules with sophisticated multifunctional shells of containing 5-10 wt% of drugs and having the ability for switchable release with few to tens of hours. In most of the recent published papers, such LbL capsules have a diameter of a few micrometers. It appears to be too large for blood injection but these LbL microcapsules have a very thin flexible wall and they have a certain ability to squeeze through narrow capillaries similar to
blood cells. Another tendency is making very thin LbL-shells (two-three polyelectrolyte layers of 5-10 nm) on 100-200 nm diameter cores of low soluble drugs (often anti-cancer drugs). In this encapsulation, LbL coating provides a strong surface charge producing stable nanocolloids of initially poorly soluble materials. It is this second approach for low solubility cancer drug nanoformulations that will be further developed in this dissertation.
CHAPTER 3

INSTRUMENTATION AND MATERIALS

LbL assembly was carried out using polyallylamine hydrochloride (PAH), polyethyleneimine (PEI), protamine sulfate and chitosan, as positively charged polyelectrolytes and bovine serum albumin (BSA), algic acid, and sodium polystyrene sulphonate (PSS), as negatively charged polyelectrolytes (used at concentration of 2 mg/mL). All polyelectrolytes and albumin were purchased from Sigma-Aldrich except paclitaxel is purchased from LC Laboratories Inc (Woburn, MA), curcumin is provided by Sabinsa Corporation (East Windsor NJ). Deionized water and phosphate buffered saline (PBS) buffer were used at pH 7.2. Ultrasonicator UIP1000hd (Heilscher, Germany) with titanium sonotrode was used at a power of 15 W/cm². During the experiments, the temperature was controlled at 25-30 °C.

Surface potential (zeta potential) and particle size measurements (by light scattering) were performed using ZetaPlus microelectrophoresis (Brookhaven Instruments, Co.). Additionally, we used Precision detectors PDExpert light scattering Workstation to check the radius of gyration of our drug nanoparticles. A field emission scanning electron microscope (Hitachi S 4800) was used for particle imaging. XRD experiments were performed with the help of a Bruker D8 Discover X-ray Diffractometer to determine the crystalline structure of drug nanoparticles.
The drug release rates of nanocapsules with different shell composition were measured using standard 1 mL horizontal diffusion chambers with 0.2 μm cellulose acetate membranes. The drug dispersion was placed to the side of the diffusion chamber containing a magnetic stirrer and the drug was released against the same volume of PBS, pH 7.2 to mimic the sink conditions expected in vivo. The concentration of released drugs in PBS was dissolved in ethanol at 1:1 (v/v), centrifuged to remove insoluble polyelectrolytes and measured with a UV spectrophotometer (Agilent 8453 Wavelength range 190-1100 nm). Curcumin was measured at 490 nm, and paclitaxel was measured at 245 nm. Also, the same measurements were done to calculate product yield at the end of sonication. Further, we describe the instruments used in this work in more detail.

### 3.1 Ultrasonicator

A Hielscher UIP1000hd ultrasonic processor, Figure 3-1, was used to prepare nanoparticles in this research.
When ultrasonic energy is applied to liquids, and if amplitude and acceleration are high enough, the phenomenon of cavitation occurs. The cross-section of sonotrode used corresponded to the surface area of the drug dispersion to maximize ultrasonication power. The liquid bursts and vacuum bubbles are generated during the alternating high-pressure and low-pressure cycles. When these small bubbles cannot absorb more energy, they implode during a high-pressure cycle, so pressures up to 1,000 bar and shock waves as well as liquid jets of up to 400 km/h are reached locally. These intense forces, caused by ultrasonic cavitation, take effect on the enclosing
droplets and particles. The main objective of power ultrasonics consists of cavitation forces, with heating being mostly a welcome side-effect. Cavitation and the effects described above cause interparticle collision.

3.2 Zeta Potential Analyzer

A ZetaPlus zeta potential analyzer (Brookhaven Instruments, Co), Figure 3-2, was used to measure the surface charge of nanoparticles during the LbL assembly process. This instrument also can be used to measure the particles hydrodynamic diameter using light scattering.
Zeta potential measurement was calibrated using a BI-ZR3 zeta potential reference material provided by Brookhaven Instruments, Co.

100 mg of BI-ZR3 was added to 20 mL of the 1 mM KCl, result in 5mg/mL concentrate. Then the concentrate dilutes to $1.25 \times 10^2$ mg/mL. This standard sample is used to have a mean zeta potential value of 53 mv ± 4 mv, and 300 nm mean size.

Zeta potential is used as a surrogate for surface change and is often measured by observing the oscillations in signals that result from light scattered by particles located
in an electric field, though there are other approaches. There are a number of instrumental configurations by which this is achieved, mostly using a doppler shift, and the users should familiarize themselves with the particular approach implemented in their equipment. Instrumentation concerns aside, the need for dilution begs the question of what is an appropriate diluent, because its choice can profoundly influence the surface chemistry and thus the results. This analyzer was calibrated using a BI-ZR3 reference material from Brookhaven Instruments, Co.

### 3.3 Dynamic Light Scattering

The Precision detectors PDExpert light scattering workstation Figure 3-3 is a multi-detector light scattering platform that can be employed for light scattering measurements on a static sample (e.g. a test tube) or for flow through measurements (e.g. high performance liquid chromatography, gel permeation chromatography and size exclusion chromatography). The workstation is designed to provide the ultimate in detection for characterization of polymers, nanoparticles, lipids, colloids and proteins.
Figure 3-3 Precision detectors PDExpert light scattering workstation

DLS, also known as photon correlation spectroscopy (PCS) or quasi-elastic light scattering (QELS) records the variation in the intensity of scattered light on the microsecond time scale. This variation results from interference of light scattered by individual particles under the influence of Brownian motion, and is quantified by compilation of an autocorrelation function. This function is fit to an exponential, or some combination or modification thereof, with the corresponding decay constants being related to the diffusion coefficients. Using standard assumptions of spherical size, low concentration, and known viscosity of the suspending medium, particle size is calculated from this coefficient. The advantages of the method are the speed of analysis, lack of required calibration, and sensitivity to submicrometer particles. Drawbacks include the necessity of significant dilution to avoid artifacts, the need for cleanliness in sample preparation, the mathematical instability of the procedure used to extract decay constants, and the possible influence of interparticle interactions. DLS is a stand-by
method for those working in the area of nanoparticles because of the simple measure requirement

3.4 X-Ray Diffractometer

A Bruker D8 X-Ray diffractometer was used to determine the crystal structure of the nanoparticles (Figure 3-4)

![Bruker D8 Discover X-ray diffractometer](image)

Figure 3-4 Bruker D8 Discover X-ray diffractometer

3.5 SEM

Figure 3-5 shows the Hitachi SEM which was used for nanoparticles visualization. Diluted drug nanoparticles dispersion was dropped on a suitable substrate and coated with a ca 0.5 nm gold layer to provide conductivity.
This SEM also has an energy-dispersive X-ray spectroscopy (EDX) detector (EDAX Sapphire). EDX Analysis can be used to determine the element composition of the sample.

### 3.6 Ultra Violet Spectrophotometer

An UV-vis spectrophotometer (Agilent 8453), Figure 3-6, was used to measure the concentration of drug in the release test. The drug release test measures the pharmacodynamic diffusion of the nano drug particle in a side-by-side diffusion chamber.
Figure 3-6 Agilent 8453 UV-Vis spectrophotometer
CHAPTER 4

DRUG NANOPARTICULATION VIA TOP-DOWN APPROACH

Nanoparticle drug carriers were developed using a combination of ultrasonication and encapsulation with synthetic and biodegradable polyelectrolytes. Two different approaches to attain the desired featured properties are the “top-down” and “bottom-up” synthetic methods. These two methods are described in Chapters 4 and 5. A common feature of these two related methods is ultrasonication-driven formation of drug nanocores accompanied by a simultaneous polycation coating providing aqueous colloidal stability. The “top-down” method was more efficient in the preparation of large amounts of 200-250 nm diameter paclitaxel capsules, and the “bottom-up” approach allowed for the formation of smaller capsules of ca. 100 nm diameter but with less product yield. Some sections of these two chapters were published in papers written by the author of this dissertation and will be correspondingly referred [148] and [149].

4.1 Methodology

Powerful ultrasound generates micro-bubbles in a liquid. These micro-bubbles collapse in microseconds. If any solid particle is near the bubble during the collapsing, jets of fluid and shock waves will hit the particle and break it up. While adding polyelectrolyte into the solution, the typically negative surface of the newly formed
drug surface will help to keep particles from aggregation. Thus, a smaller particle size can be achieved with a better size distribution. Because the ultrasonication process breaks down the particles, it is a mechanical process. The formed particles will have a wide range of sizes. Both power and sonication time effect the nanoparticles' size distribution. In general, the higher the power and the longer the time, the smaller the particles will be. But if one stops sonication, particles will aggregate. To prevent the aggregation during the sonication and increase the efficiency of the sonication, we added polycations that adsorbs onto the drug nanoparticles and prevents re-aggregation. The minimum amount of polycation needed for complete coverage was calculated in Appendix A. The surface zeta potential of the particles changed to positive during the polycation adsorption and reached of ca. +40mV.

For drug encapsulation, anionic sodium polystyrene sulfonate (PSS) of MW 70 KDa and cationic poly(dimethyldiallyl ammonium chloride) (PDDA) of MW 100 KDa were sequentially adsorbed onto the particles of different drugs at pH 6, and then the desired number of layers in the capsule shell was fabricated. Biodegradable polyelectrolytes that were used for the LbL assembly are protamine sulfate and chondroitin sulfate. The multilayer shells that are fabricated on the drug help in prolonging the release of the drug. Figure 4-1 shows the scheme for top-down approach. The verification of the alternation of surface charges and particle size were done with a ZetaPLus Brookheaven microelectrophoretic zeta-potentiometer. A visualization of the fabricated microcapsules was completed using SEM.
4.2 Curcumin Nanoformulation

Curcumin is a well known natural compound traditionally used as a food additive or a health nutrient supplement in many oriental countries. Recently, its anti-cancer activity was recognized [150]. It is a low soluble compound (the aqueous solubility is ca 0.01 mg/mL). The curcumin structural formula is shown in Figure 4-2.

![Figure 4-2 Structural formula for curcumin](image-url)

Figure 4-2 Structural formula for curcumin.
4.2.1 Preparation of curcumin nanoparticles

The following experimental step-by-step sequence was used to prepare nanoparticles of curcumin:

1) 10 mg curcumin powder was mixed with 10 ml of DI water
2) The mixture was pre-sonicated for 5 min to form curcumin suspension
3) 2 mL of 1.5 mg/mL cationic PAH were added to the suspension
4) 45 min sonication was applied
5) The curcumin nanoparticles were washed twice with DI water using centrifugation at 7000 rpm (5204 g rcf) for 10 min to separated nanoparticles from supernatant and re-dispersed in 20 mL of DI water
6) 2 mL of 3 mg/mL anionic PSS were added to the mixture, 10 min of reaction time was allowed for the polyelectrolyte adsorption
7) The supernatant was removed by centrifugation at 7000 rpm, Nanoparticles were washed with DI water and re-dispersed
8) Steps 6-7 were repeated for next layer of cationic PAH
9) Steps 6-8 were repeated several times to achieve the desired number of polyelectrolyte layers in the coating

Instead of cationic PAH and anionic PSS, biodegradable polyelectrolytes such as protamine sulfate (PS), bovine serum albumin (BSA) and chondroitin sulfate (ChS), may be used for the coating.

The alternation of electrophoretic ($\xi$) potential demonstrates a step-wise formation of the LbL-shell consisting of cationic PAH and anionic PSS on curcumin nanoparticles. Figure 4-3 shows a typical zeta potential change during the ultrasonic assisted LbL assembly process. Each sample was measured 10 times. The standard
deviation was given by the zeta potential analyzer. After the initial -50 ± 2 mV for bare curcumin particles, PAH adsorption during the first step of nanoparticles synthesis converts the potential to +30 ± 2 mV. Next, anionic PSS adsorption changes the potential to -53 ± 2 mV, followed by +20 ± 2 mV with PAH, and again -50 ± 2 mV with PSS. Therefore, a multilayer coating of polycations and polyanions with composition of (PAH/PSS)₂ was coated onto the curcumin nanoparticles and the enhanced surface potential of -50 mV was reached. This value is well above commonly accepted colloidal stability threshold of (±) 30 mV [149].

Figure 4-3 ζ-potential alternation during LbL-shell formation of cationic PAH and anionic PSS on curcumin nanoparticles. Standard deviation shows the same sample run 10 times on zeta potential analyzer.

Separate QCM analysis of the LbL assembly process for these polyelectrolytes on silver plated 9-MHz Quartz Crystal Microbalance resonators (USI-System Instr, Japan) demonstrated a thickness increment of 2 0 ± 0.3 nm for a PAH/PSS bilayer, and
the total thickness of the two-bilayer shell on the curcumin nanoparticles may be estimated as ca. 4 nm. Any shell composition may be achieved with further alternate adsorption of polycations and polyanions [149].

In another experiment, curcumin nanocapsules with two bilayer shells of biocompatible protein materials were produced. A positive layer in the shell was generated using protamine sulfate (PS), while bovine serum albumin (BSA) formed a negative layer. Total composition produced was \((\text{PS}/\text{BSA})_2\). For these LbL nanocapsules, zeta potential also regularly alternates between +30 mV and -50 mV providing high colloidal stability of the samples [149]. The dispersion of the nanoparticles with the concentration of 0.2 g/mL was stored in DI water for two weeks without precipitation.

The yield of the nanoparticles was about 30-40 % which means that, if curcumin concentration at the beginning of the process was typically 1 mg/mL, then, in the product, it was of about 0.3-0.4 mg/mL.

Figure 4-4 shows SEM image of the formed curcumin nanoparticles. One can see that, in diluted dispersions, the nanoparticles' size is from 50-120 nm (left) and, upon the drying of the concentrated sample, some aggregation occurs (right image).

Figure 4-4 SEM image of the formed curcumin nanoparticles (left) diluted sample, and (right) concentrated sample
4.3 Nanoformulation of Paclitaxel

Paclitaxel (Figure 4-5) is an efficient anti-cancer drug, but due to very low solubility, there is not effective way for its delivery. However, with paclitaxel nanoformulation it is feasible to increase the drug concentration a hundred times (up to a few mg/mL).

Figure 4-5 Structural formula for paclitaxel

Figure 4-6 shows a typical zeta potential change during the assembly. Each sample was measured 10 times. The standard deviation was given by the zeta potential analyzer. One can see the zeta potential changes for the LbL assembly of polyelectrolyte multilayer shell on paclitaxel nanoparticles. Initially, the surface potential of the paclitaxel nanoparticles was -21 mV. After deposition of the first cationic PAH layer (with simultaneous ultrasonication) we obtained the particle surface potential of 24 ± 3 mV. After deposition of the second layer, anionic polyelectrolyte layer (PSS), we increased the magnitude of zeta potential to 41 ± 3 mV, and finally, at the last deposition step a coating with biodegradable chitosan/alginate acid (blue line) or
albumin (red line) gave us a strong negative surface charge of the encapsulated paclitaxel of -46 ± 4 mV and -32 ± 3 mV. This high surface potential provided for the stability of the developed paclitaxel nanocolloids for at least two weeks at concentrations of 0.5 mg/mL.

![Figure 4-6 ξ-potential of paclitaxel coated with two different bilayers of PAH-PSS-PAH-BSA and PAH-PSS-chitosan-alginic acid (using top-down approach). Standard deviation shows the same sample run 10 times on zeta potential analyzer.]

In Figure 4-7, one can see the SEM image of the initial micronized sample of paclitaxel. It consists of needle-like rods with diameter of ca 100 nm and length of 2-3 μm. During sonication-assisted LbL encapsulation, we obtained rather homogeneous particles with average sizes of 100 × 100 × 200 nm. This particle suspension is collapsed during the drying of the sample, but the aqueous dispersion itself is stable. It is interesting, that due to very low solubility, it is possible to keep the paclitaxel sample without dissolution for weeks because in such a restricted volume the supernatant...
saturation is reached preventing further particles dissolution. Only in a big solvent volume (under sink release conditions), can paclitaxel nanoparticles be partially or completely dissolved. These particles are less than 300 nm and are in accordance with the minimum particle size allowed by FDA for medical injections.

Figure 4-7 SEM image of orginal paclitaxel (left) and after ultrasound assisted LbL encapsulation with PAH/PSS/chitosan/alginate acid (right)
CHAPTER 5

DRUG NANOPARTICULATION VIA BOTTOM-UP APPROACH

This technology is our new invention. It was disclosed to LaTech 1) Z Zheng, Y Lvov “Sonication synthesis of polyelectrolyte coated nanoparticles through mixing molecular solutions with bad solvents,” September 30, 2008-27, and 2) Y Lvov, Z Zheng, V Torchilin “Pachtaxel and atavoquone nanoparticle production through ultrasonication with gradual desolvation assisted with polycation coating. Synthesis of the mixed drugs nanoparticles,” December 1, 2008-30 US patent application by V Torchilin, Y Lvov, Z Zheng “Stable Aqueous Nanocolloids of Pachtaxel and Atavoquone,” was filed by Louisiana Tech University and Northeastern University on April 25, 2009. Some sections of this chapter were published in a paper written by the author of this dissertation and will be correspondingly referred [149] Z Zheng, X Zhang, D Carbo, C Clark, C-A Nathan, Y Lvov, Langmuir, v 26, 7679-7681, 2010 “Sonication assisted synthesis of polyelectrolyte coated curcumin nanoparticles”

5.1 Methodology

The drug powder was dissolved in ethanol/water solution. After drug has been completely dissolved, we added aqueous polycations, poly(allylamine hydrochloride) (PAH) or biodegradable protamine sulfate (PS), and started ultrasonication with a UIP1000, Hielscher instrument, at energy density of 100 Wt per mL of solution. During
the sonication, water was slowly added into the solution. Because of the added water, the solvent becomes more polar, causing a decrease of drug solubility, and eventually, its concentration exceeds the solubility threshold resulting in the drug supersaturated conditions. Then, crystal nucleation starts. Under high power ultrasonication, the drug particle growth ceases at the initial stages [149]. An adsorption of polyelectrolytes onto the drug nanocrystals establishes a barrier for their further growth and aggregation. The minimum amount of polyelectrolytes needed for complete coverage was calculated in Appendix A. Obtained drug crystal particles were stable and did not aggregated after sonication was stopped. We assume that it was because of the increase of surface charge provided by the adsorbed polyelectrolyte layer. After 45 min of sonication, drug nanocrystals were separated from the solution by centrifugation and re-suspended in DI water. Additional polyelectrolyte multilayers were built on the curcumin nanoparticles by alternate adsorption of polyamions and polycations (LbL shell assembly). For biocompatible capsules, an alternate adsorption of cationic protamine sulfate (PS) and anionic bovine serum albumin (BSA) were used (Figure 5-1).
The drug was dissolved in 60% ethanol at a concentration of 2 mg/mL. We present here the results for low solubility anti-cancer drugs curcumin and paclitaxel. Ultrasonication was applied for 45 min while slowly adding water at the rate of 0.2 mL/min [149].

5.2 Curcumin Nanoformulation

5.2.1 Nanocurcumin preparation

The drug/shell multilayer structure is curcumin/PS/BSA/PS/BSA.

The following experimental step-by-step sequence was used to prepare nanoparticles of curcumin.
1) 10 mg curcumin were dissolved in 10 ml of 60 % ethanol/water (optionally, we also used acetone)

2) The solution was presonicated for 5 min to completely dissolve the curcumin

3) 6 mL of 0.2 mg/mL aqueous cationic PS, pH 6.5 were slowly added at a speed of 0.5 mL/min during 30 min sonication. This is the key step of the procedure initiating the particle nucleation.

4) The nanoparticles were washed twice with DI water using 7000 rpm centrifugation to separate the nanoparticles from supernatant.

5) 3 mg of anionic BSA were added to the mixture and allowed to adsorb for 10 min.

6) The nanoparticles were washed twice with DI water using 7000 rpm centrifugation before coating with aqueous cationic PS.

7) 3 mg of PS were added to the mixture and allowed to adsorb for 10 min.

8) Steps 4-7 were repeated to achieve a given number of layers.

Figure 5-2 shows a typical zeta potential change during the ultrasonic assisted LbL assembly process. Each sample was measured 10 times. The standard deviation was given by the zeta potential analyzer. Due to the adsorption of cationic PAH, the surface potential of these nanoparticles was positive, ca +30 mV. Further coating with PSS increased the zeta potential magnitude to -52 ± 4 mV. High surface charge increases colloidal stability for this formulation. For example, in an aqueous curcumin nanocolloid of 0.5 mg/mL concentration a stable dispersion of the drug was preserved for one month. In Appendix B, we calculated the average distance between particles.
under different conditions. Low concentration means longer distance between particles, which usually means better stability.

![Graph showing zeta potential alternation during LbL coating of curcumin (pH 6.5). Standard deviation shows the same sample run 10 times on zeta potential analyzer.](image)

Curcumin nanoparticles of rectangular shape were obtained. Edges from 60 nm to 90 nm (Figure 5-3) and average edge size of 80 ± 20 nm were estimated with SEM imaging processing software Quartz PCI (Hitachi) and light scattering experiments (Brookhaven Instruments, Co, ZetaPlus). The rectangular shape of the nanoparticles is associated with the crystalline nature of the obtained curcumin particles [149].
To examine the crystal structure of the curcumin nanoparticles, X-ray powder diffraction analysis was carried out with a Bruker-D8 XRD instrument. Bragg peak positions in the X-ray pattern obtained from the dried nanoparticles powder coincided with the peak positions for bulk curcumin powder, but the peaks were wider due to smaller crystallite size (Figure 5-4). These X-ray data indicate that the crystal structure of curcumin was preserved, and polycations added during drug crystal formation did not form a complex with curcumin molecules but only covered the crystals surface. We assume that polycations were layered predominantly on the crystal surface, as it follows from electrophoretic (ξ-potential) data given below [149].
5.3 Pachtaxel Nanoformulation

5.3.1 Preparation of nanopachtaxel

The following experimental step-by-step sequence was used to prepare nanoparticles of pachtaxel

1) 10 mg of pachtaxel were dissolved in 10 mL of 60% ethanol/water solvent

2) The mixture was presonicated for 5 min to completely dissolve pachtaxel

3) 6 mL of aqueous 0.2 mg/mL cationic PS (pH 6.5) was added at a speed of 0.5 mL/min during 45 min sonication. This is the most important stage of the formulation
4) The nanoparticles were separated from supernatant using 7000 rpm centrifugation for 10 min and washed twice with DI water. Then the nanoparticles were redispersed in 10 ml of DI water.

5) For the next BSA layer, 3 mg BSA were admixed to the dispersion for 10 min.

6) Step 4 was repeated.

7) A layer of cationic protamine sulfate was deposited in the same way as in step 5.

8) Step 4 was repeated.

9) Steps 5-8 were repeated to obtain the desired coating structure.

Pacitaxel was dissolved in a "good" solvent (60 % ethanol/water or 60 % acetone/water). After dissolution of the drug at high concentration, ultrasonication was started with aqueous polycation slowly added to the solution. With an increase of water concentration, solubility of pacitaxel decreased, reached saturation, and the nucleation began resulting in the formation of nano-size particles.

Powerful sonication prevents formation of larger drug particles and polycation adsorption provides for a surface charge sufficient for colloidal stability. After a 45 min treatment, the drug particles were centrifuged at 7,000 rpm for 10 min and re-suspended in distilled water. The second layer of anionic polyelectrolytes was deposited to maximize the capsule surface potential. Nonreacted polyanions were removed by centrifugation and pacitaxel nanoparticles with the average particle size of 100 nm were obtained. Additional polyelectrolyte layers may be further built up on the drug nanoparticles using the traditional LbL process without sonication. Obtained pacitaxel nanocolloid was kept in a small volume of saturated solution to prevent drug release.

[149]
Figure 5-5 shows a typical zeta potential change during the Ultrasonic assisted layer-by-layer assembly process. Each sample was measured 10 times. The standard deviation was given by the ZetaPlus zeta potential analyzer (Brookhaven Instruments, Co). The alternated zeta potential during formation of LbL nanoshells on paclitaxel nanocores has a minimal potential of -35 mV.

![Zeta Potential Change Diagram](image)

Figure 5-5 $\xi$-potential change during the LbL encapsulation of paclitaxel. Standard deviation shows the same sample run 10 times on zeta potential analyzer.

Figure 5-6 shows SEM image of the resulting nanocapsules with average diameter of 90 ± 20 nm.
Figure 5-6 SEM image of paclitaxel nanoparticles with shells of (PS/PSA)$_2$ (left); same sample showing aggregation of particles at another site (right)

Figures 5-7 shows the SEM images of paclitaxel particles prepared with the bottom-up approach, then using centrifuge to separate large particles and small particles.

Figure 5-7 SEM image of paclitaxel in 60% ethanol sonicate for 45 min before (left) and after (right) centrifuge
CHAPTER 6

PROCESS OPTIMIZATION

6.1 Ultrasonication Time

The first parameter we optimized was sonication time. It is logical to assume that the longer the sonication, the smaller particles one can get. However, in the "top-down" approach, even many hours of sonication did not result in particles less than 200 nm. Probably, there is a limitation preventing further splitting of the drug particles. In ref [151], it was suggested that this minimal size may be related to the nucleation size of vapor bubbles during sonication. The only improvement which we suggest in future work could be a modification of the cavitation process in sonication by changing solution properties and vapor bubble formation conditions (for example, with increased pressure). Finally, the optimized sonication time for the nanoformulation of curcumin and paclitaxel was chosen to be 30-45 min. Another factor, requiring the limitation of sonication time is sample pollution with depleted submicron particles of titanium oxide. This pollution is developing with sonication times above one hour and then additional sample purification to eliminate titanium alloy particles is needed. Fortunately, it is relatively easy due to different particle densities. As shown in Figure 6-1, the particle size decreases when the sonication time increases. The result was achieved after seven measurements at each data point. The standard deviation was given by the 90Plus particle sizer.
6.2 Water Add-in Speed and Drug Concentration

To minimize the curcumin particle size, we prepared a series of samples processed under various conditions (different ethanol/water ratios, drug concentrations, ultrasonication power, time, and speed of the solvent worsening for crystallization initiation) Two major factors that affect the crystal size were the rate of water addition (speed of the solvent worsening) and an initial curcumin concentration These factors were optimized Figure 6-2 gives the dependence of particle size on the rate of water addition The result was achieved after seven measurements at each data point The standard deviation shows the same sample run seven times on 90Plus particle sizer (Brookhaven Instruments, Co)
The water addition rate was varied from 0.05 mL/min up to 0.4 mL/min for the sample volume of 50 mL, and the higher rate resulted in the formation of larger particles. We observed particles of ca. 320 nm average size at 0.4 mL/min rate versus ca. 120 nm particles for the 0.05 mL/min rate.

An increase of curcumin concentration in the initial solution also resulted in larger nanoparticles as shown in Figure 6-3. The result was achieved after seven measurements at each data point. The standard deviation shows the same sample run seven times on 90Plus particle sizer (Brookhaven Instruments, Co). Slightly larger sizes of curcumin nanoparticles, as obtained with the light scattering technique (ca. 100 nm) as compared with mean 80 nm size average over thirty particles in the SEM image.
may be explained by the fact that light scattering is more sensitive to the admixture of larger particles in the sample, which were excluded in the SEM estimations [149].

Figure 6-3 Dependence of curcumin particle size on curcumin concentration. Standard deviation shows the same sample run seven times on 90Plus particle sizer.
CHAPTER 7

DRUG RELEASE

We use a set of side-by-side diffusion cells (PermeGear, Inc) to measure the drug release profile.

The setup is shown in Figure 7-1. We use a 0.1 μm membrane to separate the two chambers. The joint between the sections was sealed with silicone gel. We fill the receptor chamber with DI water and fill the donor chamber with the drug sample and start timing. After a certain time period, we take out all the solution in the receptor chamber and refill it with DI water again. Each solution that is taken out from the receptor chamber is labeled (s1, s2, ..., sn-1)) then measured for drug concentration with UV spectrophotometer (Agilent 8453). A standard curve is measured earlier to establish the relationship between concentration and absorption, and a linear relationship was found. At the end of the release test, both solutions from the receptor chamber (sn) and the donor chamber (sd) were taken out and measured for concentration. The release rate was established by accumulating the amount of the drug taken out from the receptor at time x.

\[
\text{Total amount of drug} = S_1 + S_2 + \ldots + S_{n-1} + S_d
\]

\[
\text{Release rate at time } x = \frac{(S_1 + S_2 + \ldots + S_x)}{\text{Total amount of drug}}
\]
7.1 Curcumin Release from Nanocapsules

The drug release profile of the curcumin LbL-nanocolloids with the (PS/BSA)$_2$ coating was analyzed in a diffusion chamber (sink conditions) (Figure 7-2). 50% drug release from LbL coated nanoparticles was reached in seven hours and 60% release was reached within ca. 20 hours. This release is slower than for nano-curcumin powder without the LbL shell or the original micronized curcumin. We have to emphasize that the main goal of our work is not slowing down of the drug release rate but the formulation of stable drug nanocolloids with injectable particle size (below 300 nm). However, a slower release time is useful and is an indirect proof of the shell formation providing a diffusion barrier for the particles and slowing down their dissolution.

Figure 7-1 Release test side-by-side diffusion cell set up (Scheme of side-by-side cells kindly provided by PermeGear, Inc.)
Figure 7-2 Release profiles of curcumin in original micropowder form, after nanoparticulation and prepared with LbL nano-encapsulation (the shell composition (PS/BSA)$_2$)

The release profile fits the Peppas model $M_t / M_\infty = K t^n$, where $M_t$ is the amount of drug released at time $t$, $M_\infty$ is the amount of drug released at infinite time, $n$ is the exponent characteristic of the release mechanism, and $K$ is a constant. Detail of the fitting can be seen in Appendix C. The obtained value for $n$ less than 0.5 indicates that the release mechanism is Fickian diffusion.

### 7.2 Paclitaxel Release from Nanocapsules

The release profiles of the original paclitaxel powder, paclitaxel nanocolloids with one polycation layer and three polycation/polyanion bilayer coating were analyzed.
in standard sink conditions. The fitting of the release curves were accomplished with exponential Peppas' model. Within eight hours, 70% of original paclitaxel powder was released (Figure 7-3).

![Release curves for the original micronized powder of paclitaxel, uncoated paclitaxel nanoparticles (only one PAH layer adsorbed for colloidal stabilization) and nano-encapsulated paclitaxel with (PAH/BSA)$_2$ shell composition](image)

Nanoparticulated paclitaxel coated with one polyelectrolyte layer leads to slightly faster release due to a smaller particle size in nanoformulation, as compared with the micrometer size of the original paclitaxel. Paclitaxel nanocolloids, coated with two bilayers of PAH/BSA, showed a lower drug release rate due to the increasing thickness of the capsule wall. For example, in eight hours, only 40% of the two layers...
coated sample was released as compared with 80 % for the one layer coated sample. The LbL encapsulation technique allows for control of the drug release rate from polyelectrolytes-stabilized nanoparticles by changes in the number of coating layers or the shell composition [148].
CHAPTER 8

CONCLUSIONS

Two methods (top-down and bottom-up) of nanoparticle formulation for low water-solubility materials were developed and applied for nanoformulation of anticancer drugs curcumin and paclitaxel. The resulting drug nanoparticles have a diameter of 100-220 nm and are stable in water.

In the first, top-down method, the drug powder was broken up by ultrasound through the collapse of microbubbles (with jet fluid and shock waves). By adding polycations into the solution, the slightly oxidized negative surface of the newly formed particles was recharged positively to a higher surface potential which prevented particles from aggregating. This approach was proposed earlier, and we applied it to the new drugs paclitaxel and curcumin, the resulting nanoformulated drug had diameters of ca. 200-250 nm.

In this work we pioneered the second bottom-up nanoformulation method. The drug was dissolved in an organic solvent that is miscible with water (ethanol or acetone) and its nucleation was initiated by the gradual decrease in the solubility of the solution with addition of aqueous polyelectrolyte. The process was assisted by ultrasonication. Similarly to the first method, the polyelectrolytes coating induced higher surface charge on the formed nanoparticles and provides nanocolloid stability. This coating was extended to achieve multilayer encapsulation through alternate adsorption of oppositely
charged synthetic and biodegradable polyelectrolytes (polyallylamine, sodium polystyrenesulfonate, chitosan, bovine serum albumin, protamine sulfate, and alginic acid). Unlike the commonly used emulsion methods, our ultrasonication assisted layer-by-layer nano-encapsulation method allowed for achieving nanoparticles of a much smaller size. We obtained crystalline nanoparticles with an average size of 80 nm, and zeta potential of +30 mV or -50 mV (depending on the number of polyelectrolyte layers in the shell), which ensured the stability of the nanocolloids in water for weeks at a concentration of ca. 0.2 mg/mL. Formation of shells with two bilayers of biocompatible polyelectrolytes allowed for slow drug release during ca. 20 hours.

The product efficiency of the top-down approach was ca. 50%, which was higher than the efficiency of the bottom-up approach (ca. 20%). The bottom-up approach leads to increased losses due to the formation of larger particles at a fast nucleation rate. Larger were removed by centrifugation thus decreasing the yield of the nanoparticles final product.

Ultrasound assisted layer-by-layer nano-encapsulation is a promising technique to produce stable 1-2 mg/mL concentration nanocolloids of poor water soluble drugs, like paclitaxel, curcumin, and others. The particle size in such drug formulation is reduced from the initial tens of micrometers in the drug powders to 100-200 nm which allow clinical injection. Nanoparticle coating with natural polyelectrolytes (polysaccharides) has the potential to increase drug circulation time and availability at the tumor site. Layer-by-layer encapsulation was carried out with biodegradable polyelectrolytes protamine sulfate, alginic acid, chitosan and bovine serum albumin. The drug particle size can be optimized using either top-down or bottom-up sonicated LbL-treatment.
Future work

The stability of nanocolloids at a concentration of 2 mg/mL in buffers with 0.1 M salt concentration needs to be improved. Our formulation allowed stable nanocolloids only in solutions with low salt concentrations. The free reactive groups of biocompatible polyelectrolytes (amine or acidic) at the outermost layer may help to bind PEG for longer particle circulation in blood or receptors for targeted drug delivery.

Further process improvement of both top-down and bottom-up techniques can be achieved by increasing the sonication power. Ultrasonication efficiency depends on the shock wave power released on the drug particle surface due to the collapsing of gas microbubbles. One can choose additives which will increase the number of bubbles and decompose without damaging the original drug product. Another approach to increase sonication power is working under elevated pressure, which may be reached using a compressed gas atmosphere. New graduate students will work on constructing a high gas pressure chamber for ultrasonication.

For drug nanoparticles targeting, we are planning to use a chemically active layer (with acidic, amine groups) as the outside LbL coating layer to link antibody to target drugs to specific cancer cells.

Publications on the dissertation


Ten poster reports at national and international conferences (with published abstracts)


V Vergaro, I Palama, Z Zheng, R Cingolani, Y Lvov, S Leporatti
“Cytomechanical modifications induced by drug-loaded carriers uptake by breast cancer cells” 2009 European Biophysical Society Meeting, Genova, Italy, July 11-15, 2009


Patents and disclosures based on this work

US patent application by V Torchilin, Y Lvov, Z Zheng “Stable Aqueous Nanocolloids of Paclitaxel and Atavoquone,” jointly filed by Louisiana Tech University and Northeastern University on April 25, 2009
LaTech disclosures


2) Y Lvov, Z Zheng, V Torchulin "Paclitaxel and atavoquone nanoparticles production through ultrasonication with gradual desolvation assisted with polycation coating Synthesis of the mixed drugs nanoparticles," December 1, #2008-30
APPENDIX A

POLYELECTROLYTE REQUIRED FOR NO-WASH PROCESS
To estimate the minimum amount of polyelectrolyte needed for complete coverage of nanoparticles we perform the calculation in Table A-1. In this case we calculate the PAH needed to complete coat 2 g of pacltaxel which have a rectangular sharp and average edge of 300 nm length.

Table A-1 Minimum amount of polyelectrolyte needed for coating

<table>
<thead>
<tr>
<th>Assume PTX density=</th>
<th>1.5</th>
<th>g/cm³</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTX weight</td>
<td>2.00E-02</td>
<td>g</td>
</tr>
<tr>
<td>average single PTX size</td>
<td>3.00E-05</td>
<td>cm</td>
</tr>
<tr>
<td>average single PTX size nm</td>
<td>3.00E+02</td>
<td>nm</td>
</tr>
<tr>
<td>volume of PTX=w/p</td>
<td>1.3333E-02</td>
<td>cm³</td>
</tr>
<tr>
<td>single PTX volume</td>
<td>2.70E-14</td>
<td>cm³</td>
</tr>
<tr>
<td>number of PTX particle</td>
<td>4.9383E+11</td>
<td></td>
</tr>
<tr>
<td>single PTX surface</td>
<td>5.40E-09</td>
<td>cm²</td>
</tr>
<tr>
<td>total surface</td>
<td>2.6667E+03</td>
<td>cm²</td>
</tr>
<tr>
<td>thickness of PAH</td>
<td>2.00E-07</td>
<td>cm</td>
</tr>
<tr>
<td>thickness of PAH nm</td>
<td>2.00E+00</td>
<td>nm</td>
</tr>
<tr>
<td>volume of PAH</td>
<td>5.3333E-04</td>
<td>cm³</td>
</tr>
<tr>
<td>PAH density</td>
<td>1.6</td>
<td>g/cm³</td>
</tr>
<tr>
<td>PAH weight</td>
<td>8.5333E-04</td>
<td>g</td>
</tr>
<tr>
<td>PAH weight in mg</td>
<td>8.5333E-01</td>
<td>mg</td>
</tr>
</tbody>
</table>
APPENDIX B

NANOCOLLOID PARTICLE DISTANCE CALCULATION
We found that the stability of drug nano colloid was effect by the concentration of the colloid. In general, we found the lower the concentration the better the stability.

To estimate the average distance between particles at a certain concentration, we prefer the calculation in Table B-1 (for sphere sharp) and Table B-2 (for cube sharp).

**Table B-1 Average distance between sphere particles**

<table>
<thead>
<tr>
<th>Calculate particle as sphere</th>
<th>Sample 1</th>
<th>Sample 2</th>
<th>Sample 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight of drug in 1 ml solution (mg)</td>
<td>0.5</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Density of drug (mg/ml)</td>
<td>1500</td>
<td>1500</td>
<td>1500</td>
</tr>
<tr>
<td>Weight of water (mg)</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
</tr>
<tr>
<td>Concentration (mg/ml)</td>
<td>0.5</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Size of particles (nm)</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Size of particles (cm)</td>
<td>0.00002</td>
<td>0.00002</td>
<td>0.00002</td>
</tr>
<tr>
<td>Weight of each particle (mg)</td>
<td>6.28E-12</td>
<td>6.28E-12</td>
<td>6.28E-12</td>
</tr>
<tr>
<td>Number of particles</td>
<td>7.96E+10</td>
<td>3.18E+11</td>
<td>7.96E+11</td>
</tr>
<tr>
<td>Volume of each particle (round) (ml)</td>
<td>4.19E-15</td>
<td>4.19E-15</td>
<td>4.19E-15</td>
</tr>
<tr>
<td>Volume of solution outside a particle (ml)</td>
<td>1.26E-11</td>
<td>3.14E-12</td>
<td>1.26E-12</td>
</tr>
<tr>
<td>Volume of each cell (ml)</td>
<td>1.26E-11</td>
<td>3.15E-12</td>
<td>1.26E-12</td>
</tr>
<tr>
<td>Distance cm</td>
<td>0.000232</td>
<td>0.000146</td>
<td>0.000108</td>
</tr>
<tr>
<td>Distance (µm)</td>
<td>2.324897</td>
<td>1.464593</td>
<td>1.079121</td>
</tr>
</tbody>
</table>

**Table B-2 Average distance between cube particles**

<table>
<thead>
<tr>
<th>Calculate particle as cube</th>
<th>Sample 1</th>
<th>Sample 2</th>
<th>Sample 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight of drug in 1 ml solution (mg)</td>
<td>0.5</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Density of drug (mg/ml)</td>
<td>1500</td>
<td>1500</td>
<td>1500</td>
</tr>
<tr>
<td>Weight of water (mg)</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
</tr>
<tr>
<td>Concentration (mg/ml)</td>
<td>0.5</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Size of particles (nm)</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Size of particles (cm)</td>
<td>0.00002</td>
<td>0.00002</td>
<td>0.00002</td>
</tr>
<tr>
<td>Weight of each particle (mg)</td>
<td>1.2E-11</td>
<td>1.2E-11</td>
<td>1.2E-11</td>
</tr>
<tr>
<td>Number of particles</td>
<td>4.17E+10</td>
<td>1.67E+11</td>
<td>4.17E+11</td>
</tr>
<tr>
<td>Volume of each particle (cube) (ml)</td>
<td>8E-15</td>
<td>8E-15</td>
<td>8E-15</td>
</tr>
<tr>
<td>Volume of solution outside a particle (ml)</td>
<td>2.4E-11</td>
<td>6E-12</td>
<td>2.4E-12</td>
</tr>
<tr>
<td>Volume of each cell (ml)</td>
<td>2.4E-11</td>
<td>6.01E-12</td>
<td>2.41E-12</td>
</tr>
<tr>
<td>Distance cm</td>
<td>0.000288</td>
<td>0.000182</td>
<td>0.000134</td>
</tr>
<tr>
<td>Distance (µm)</td>
<td>2.884499</td>
<td>1.817121</td>
<td>1.338866</td>
</tr>
</tbody>
</table>
To show the result in 3D image we use Matlab 2007 to plot the image. The program code is shown below:

```matlab
%nanoparticles size and distance calculation
%written by zhuguo zheng
%PhD student of Biomedical Engineering of Louisiana Tech University
clc
clear all

draw 3d sphere radius \( r \) nm in \( s \) nm cube cell

[xsp, ysp, zsp] = sphere(20),

\( r = 200, \)
\( d = 1079, \)
\( s = 2000, \)
\( xsp = xsp \times r, \)
\( ysp = ysp \times r, \)
\( zsp = zsp \times r, \)

for \( i = -s \) to \( s \),
for \( j = -s \) to \( s \),
for \( k = -s \) to \( s \),
surface(xsp+i, ysp+j, zsp+k),
end
end
end
axis equal,
view([50, 20]),
```
The simulation results for 200 nm sphere paclitaxel nanoparticles at concentration of 0.5 and 5 mg/mL are shown in Figure B-1.

Figure B-1 Simulation for 200 nm sphere sharp paclitaxel concentration at 0.5 mg/mL (left) and 5 mg/mL (right)

%nanoparticles size and distance calculation
%written by zhiguo zheng
%PhD student of Biomedical Engineering of Louisiana Tech University
clc, clear all,
%draw 3d cubes edge length r nm in distance d nm in a s nm cube cell
x=[0 1 1 0 0 0,1 1 0 0 1 1,1 1 0 0 1 1,0 1 1 0 0 0],
y=[0 0 1 1 0 0,0 1 1 0 0 0,0 1 1 0 1 1,0 0 1 1 1 1],
z=[0 0 0 0 0 1,0 0 0 0 0 1,1 1 1 0 1,1 1 1 0 1],
r=200,
d=1339,
s=3000,
\textbf{Figure B-2} Simulation for 200 nm cube sharp paclitaxel concentration at 0.5 mg/mL (left) and 5 mg/mL (right)
APPENDIX C

RELEASE MODEL FITTING
For release curve in Figure 7-2 we use OriginPro 8.1 software to fit the experiment data with moding equation

In this study, we use Ritger-Peppas’ empirical Equation

\[ \frac{M_t}{M_\infty} = kt^n \]

Figure C-1 shows the fitting of experiment result using Ritger-Peppas’ empirical equation. The fitting results are shown in Table C-1.

**Table C-1 Fitting results for the curcumin release profile**

<table>
<thead>
<tr>
<th>Model</th>
<th>Ritger-Peppas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equation</td>
<td>( y = a x^b )</td>
</tr>
<tr>
<td>Reduced Chi-Sqr</td>
<td>3.48E-04</td>
</tr>
<tr>
<td>Adj R-Square</td>
<td>0.99468</td>
</tr>
<tr>
<td></td>
<td>Value</td>
</tr>
<tr>
<td>Nano curcumin</td>
<td>a</td>
</tr>
<tr>
<td></td>
<td>0.34387</td>
</tr>
<tr>
<td></td>
<td>Standard error</td>
</tr>
<tr>
<td></td>
<td>0.10581</td>
</tr>
<tr>
<td>Nano curcumin</td>
<td>b</td>
</tr>
<tr>
<td></td>
<td>0.21044</td>
</tr>
<tr>
<td></td>
<td>0.03356</td>
</tr>
<tr>
<td>Original curcumin</td>
<td>a</td>
</tr>
<tr>
<td></td>
<td>11.00387</td>
</tr>
<tr>
<td></td>
<td>37.90579</td>
</tr>
<tr>
<td>Original curcumin</td>
<td>b</td>
</tr>
<tr>
<td></td>
<td>0.01274</td>
</tr>
<tr>
<td></td>
<td>0.04171</td>
</tr>
<tr>
<td>Curcumin/(PS/BSA)_2</td>
<td>a</td>
</tr>
<tr>
<td></td>
<td>0.18261</td>
</tr>
<tr>
<td></td>
<td>0.05416</td>
</tr>
<tr>
<td>Curcumin/(PS/BSA)_2</td>
<td>b</td>
</tr>
<tr>
<td></td>
<td>0.24341</td>
</tr>
<tr>
<td></td>
<td>0.0346</td>
</tr>
</tbody>
</table>
Figure C-1 Fitting result for curcumin release

Figure C-2 shows the fitting of experiment result using Ritger-Peppas' empirical equation. The fitting results are shown in Table C-2.

Table C-2 Fitting results for the paclitaxel release profile

<table>
<thead>
<tr>
<th>Model</th>
<th>Rutger-Peppas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equation</td>
<td>$Y = a \cdot x^b$</td>
</tr>
<tr>
<td>Reduced Chi-Sqr</td>
<td>5 35939</td>
</tr>
<tr>
<td>Adj R-Square</td>
<td>0.93758</td>
</tr>
<tr>
<td>Value</td>
<td>Standard Error</td>
</tr>
<tr>
<td>Nano paclitaxel</td>
<td>a</td>
</tr>
<tr>
<td>Nano paclitaxel</td>
<td>b</td>
</tr>
<tr>
<td>Orginal paclitaxel</td>
<td>a</td>
</tr>
<tr>
<td>Orginal paclitaxel</td>
<td>b</td>
</tr>
<tr>
<td>Paclitaxel/(PAH/BSA)</td>
<td>a</td>
</tr>
<tr>
<td>Paclitaxel/(PAH/BSA)</td>
<td>b</td>
</tr>
</tbody>
</table>
Figure C-2 Fitting result for paclitaxel release
BIBLIOGRAPHY


[72] V Vergaro, E Abdullayev, R Cingolani, Y Lvov, S Leporatti
“Citobioocompatibility and uptake for clay nanotubes,” *Biomacromolecules*, vol 11, pp 820-229, 2010


T Hoshi, S Akase, J Anzai “Preparation of multilayer thin films containing avidin through sugar-lectin interactions and their binding properties,” Langmuir, vol 18, pp 7024-7028, 2002

[101] T Senzawa, K Hamada, T Kitayama, N Fujimoto, K Hatada, M Akashi


[147] H Ke, Z Xing, B Zhao, J Wang, J Liu, C Guo1, Xiuli Yue, S Liu, Z Tang, Z Dai “Quantum-dot-modified microbubbles with bi-mode imaging capabilities,” *Nanotechnology*, vol 20, pp 425105, 2009


